What is the recommended protocol for propofol infusion in status epilepticus after benzodiazepine and second‑line therapy failure?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Propofol Infusion Protocol for Refractory Status Epilepticus

For status epilepticus refractory to benzodiazepines and second-line therapy, administer propofol as a 2 mg/kg IV bolus (over 3-5 minutes), followed by a continuous infusion of 5 mg/kg/hour (approximately 80 mcg/kg/min), titrating to seizure cessation on continuous EEG monitoring. 1

Dosing Protocol

Initial Loading and Maintenance

  • Loading dose: 2 mg/kg IV bolus administered over 3-5 minutes
  • Maintenance infusion: Start at 5 mg/kg/hour (range 3-7 mg/kg/hour based on clinical studies)
  • Titration: Adjust by 1 mg/kg/hour increments every 15 minutes until seizures cease on EEG
  • Repeat bolus: May repeat 2 mg/kg bolus every 3-5 minutes if seizures persist 1, 2

The evidence shows propofol achieves seizure control rapidly—within a median of 2.6 minutes compared to 123 minutes for barbiturates 3. Target plasma concentrations associated with seizure control are approximately 14 μM (2.5 mcg/mL) 3.

Critical Management Considerations

Patient Selection and Preparation

Propofol should only be used in intubated patients who do not exhibit hypotension 1. This is a crucial safety consideration, as propofol causes dose-dependent cardiovascular depression through decreased preload and afterload 2.

Before initiating propofol:

  • Ensure adequate intubation and mechanical ventilation
  • Correct fluid deficits
  • Have vasopressor support immediately available
  • Place continuous EEG monitoring
  • Establish reliable IV access

Monitoring Requirements

Continuous monitoring is mandatory:

  • EEG monitoring: Essential for titrating therapy and detecting breakthrough seizures 4, 5, 6
  • Hemodynamic monitoring: Blood pressure, heart rate, cardiac output
  • Respiratory support: Oxygen saturation, ventilator parameters
  • Serum triglycerides: Monitor during prolonged infusions (>48 hours) as propofol contains 0.1 g fat per mL 2

Comparative Efficacy

While propofol demonstrates effectiveness in refractory status epilepticus, the evidence reveals important nuances. One Class III study showed propofol was as effective as pentobarbital (73% vs 92% seizure control), though pentobarbital had slightly higher efficacy 1. However, propofol offered a significant practical advantage: patients required only 4 days of mechanical ventilation compared to 14 days with pentobarbital 1.

Propofol also caused less hypotension requiring vasopressor support compared to barbiturates (42% vs 77%) 1, making it a more hemodynamically favorable option in many patients.

Weaning Protocol

Avoid abrupt discontinuation—this is a critical pitfall. Sudden cessation causes rapid awakening with breakthrough seizures due to propofol's short half-life 2, 3.

Recommended weaning approach:

  1. Maintain seizure suppression for 12-24 hours after last clinical or electrographic seizure
  2. Gradually taper infusion rate by 1 mg/kg/hour every 6-12 hours
  3. Continue EEG monitoring throughout weaning
  4. If breakthrough seizures occur, return to previous effective dose and maintain longer before re-attempting taper 3

Adverse Effects and Complications

Propofol Infusion Syndrome (PRIS)

PRIS is a rare but potentially fatal complication, particularly with:

  • Infusions >48 hours duration
  • Doses >5 mg/kg/hour for extended periods
  • Concurrent catecholamine or corticosteroid use 7

PRIS manifestations include:

  • Metabolic acidosis
  • Rhabdomyolysis
  • Cardiac failure
  • Renal failure
  • Hyperkalemia

Monitor for PRIS with serial creatine kinase, lactate, and metabolic panels during prolonged infusions 7.

Other Common Adverse Effects

  • Cardiovascular: Hypotension (most common), bradycardia, decreased cardiac output 1, 2
  • Respiratory: Apnea, respiratory depression—requires mechanical ventilation 1, 2
  • Metabolic: Hypertriglyceridemia with prolonged use 2
  • Injection site: Pain, tissue injury with extravasation 1

Special Populations

Elderly and Hemodynamically Unstable Patients

Use slower administration rates and reduced doses:

  • Loading: 1-1.5 mg/kg over 20 mg every 10 seconds
  • Avoid rapid boluses which increase risk of severe hypotension and apnea 2

Neurosurgical Patients

Propofol effectively reduces intracranial pressure (46% reduction in cerebrospinal fluid pressure) 2. However, maintain cerebral perfusion pressure by avoiding significant hypotension. Use slower bolus administration (20 mg every 10 seconds) combined with hyperventilation 2.

Alternative Considerations

If propofol fails or is contraindicated, alternatives include:

  • Midazolam: Continuous infusion, less hypotension than propofol
  • Pentobarbital: Higher efficacy (92%) but longer ventilation duration and more hypotension
  • Ketamine: Emerging option for super-refractory cases 8, 4, 9, 5

Evidence Limitations

The guideline evidence acknowledges that controlled data for propofol in status epilepticus remain limited, with most studies being Class III 1. Formal recommendations await higher-quality prospective randomized trials. However, the available evidence consistently supports propofol's effectiveness when used appropriately in intubated, hemodynamically stable patients, with the significant advantage of shorter mechanical ventilation duration compared to barbiturates.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.